CoreWeave, Inc. SEC Filings

CoreWeave, Inc. (CRWV) Form 4: The filing reports insider transactions by Brannin McBee on 08/22/2025. The reporting person is an officer (Chief Development Officer) and director. The filing shows acquisitions of common stock in both non-derivative and derivative form: two purchases of 250,000 and 375,000 shares reported as Code C (acquired in a transaction). The document lists resulting beneficial ownership figures and multiple indirect holdings held through trusts and family entities. The derivative section reflects Class B shares convertible into Class A shares and details underlying Class A share counts across direct and indirect holdings (including amounts held in the Brannin J. McBee 2022 Irrevocable Trust and several Canis Major/Canis Minor trusts and family entities). The form is signed by an attorney-in-fact on behalf of the reporting person.

CoreWeave insider sales under 10b5-1 plan reduced certain holdings. Brian M. Venturo, CoreWeave director, officer and 10% owner, reported multiple sales of Class A common stock executed on 08/20/2025 pursuant to a Rule 10b5-1 trading plan adopted May 21, 2025. The Form 4 lists numerous dispositions across holdings the reporting person controls or influences, including shares held directly by West Clay Capital LLC and indirectly by two irrevocable trusts for a minor beneficiary. Many sales show weighted-average prices in the mid-to-high $80s to low $90s per share, and one West Clay line reports a post-transaction beneficial ownership of 0 shares. The filing is signed by an attorney-in-fact on 08/22/2025.

Nitin Agrawal, Chief Financial Officer of CoreWeave, Inc. (CRWV), reported the vesting and settlement of 11,413 restricted stock units on 08/20/2025. To satisfy tax withholding obligations related to that vesting, 6,010 shares were sold at a weighted average price of $89.9931 (sales ranged from $89.74 to $90.00). Following the reported transactions, the filing shows 128,412 shares beneficially owned directly, 115,905 shares held directly by the reporting person’s spouse, and 57,952 shares held by the Yosemite 2025 GRAT (for which the reporting person is sole trustee and beneficiary). The Form 4 also reports 11,413 settled RSUs and a resulting count of 159,775 shares underlying derivative securities beneficially owned following the transactions.

Kristen J. McVeety, GC and Secretary of CoreWeave, Inc. (CRWV), reported multiple transactions on Form 4 reflecting the vesting and settlement of restricted stock units and related share sales to cover tax withholding. On 08/20/2025 she was credited with 4,348 Class A shares upon RSU settlement and concurrently sold 61 shares at $88.93 and 2,231 shares at $90 to satisfy tax withholding. Following these transactions she directly beneficially owns 60,865 Class A shares. Separately, 95,000 Class A shares are held indirectly in the Jackfruit 2024 GRAT, for which she is sole trustee and beneficiary.

The filing states the RSUs vest in 1/16 tranches on May 20, August 20, November 20 and February 20, with the first tranche having vested on May 20, 2025, and that the reported sales were to satisfy tax withholding arising from RSU settlement.

CoreWeave insider sale summary: The filing shows that McBee Brannin, Chief Development Officer of CoreWeave, Inc. (CRWV), sold multiple blocks of Class A common stock on 08/19/2025 under a Rule 10b5-1 trading plan adopted May 20, 2025. The transactions list a series of dispositions at weighted-average prices ranging from about $88.67 to $95.63 per share. Following these sales, the reporting person and related trusts hold varying remaining positions, with some trust-held lots reduced to zero. The Form 4 was signed by an attorney-in-fact on 08/21/2025.

CoreWeave proposes to acquire Core Scientific via a merger in which each Core Scientific share will be converted into 0.1235 shares of CoreWeave. Based on CoreWeave's July 3, 2025 closing price of $165.20, the exchange ratio implied approximately $20.40 per Core Scientific share. Completion is subject to Core Scientific stockholder approval at a virtual Special Meeting and customary closing conditions including HSR clearance and Nasdaq listing of issued CoreWeave shares. The Core Scientific board unanimously recommends voting FOR the Merger and FOR the non-binding advisory compensation proposal. Tranche 1 and Tranche 2 warrants will convert to New Tranche warrants exercisable on a cashless basis. Convertible notes holders may convert under specified events and indentures will be supplemented to add CoreWeave as guarantor. The parties currently expect closing in Q4 2025, subject to conditions.

CoreWeave, Inc. (CRWV) filing a Form 144 discloses a proposed sale of securities by an insider. The filer intends to sell 6,010 shares of Class A Common Stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $540,858.66 and an approximate sale date of 08/20/2025. The shares were acquired on 08/20/2025 as compensation in the form of restricted stock units and the payment type is listed as compensation. The filing reports no securities sold by the same person in the past three months and includes the standard attestation that the seller is not aware of undisclosed material adverse information.

CoreWeave, Inc. (CRWV) Form 144 shows a notice of a proposed sale of 2,292 shares of Class A Common Stock to be handled by Morgan Stanley Smith Barney LLC on the NASDAQ. The filing lists an aggregate market value of $206,214.73 for the shares and reports 370,470,348 shares outstanding. The shares were acquired on 08/20/2025 as compensation in the form of Restricted Stock Units and payment is recorded as compensation. The filer indicates there were no securities sold in the past three months and includes the standard representation that the selling person has no undisclosed material adverse information.

CoreWeave, Inc. (CRWV) Form 144 filing discloses a proposed sale of 281,250 shares of Common stock through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $26,125,312.50. The shares were acquired as Founders Shares from the issuer on 12/27/2023 and payment was recorded on the same date. The filing lists 370,470,348 shares outstanding and indicates the approximate date of sale as 08/20/2025. No securities were reported sold in the prior three months, and the filer affirms they do not possess undisclosed material adverse information.